GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CMG Pharmaceutical Co Ltd (XKRX:058820) » Definitions » Beneish M-Score

CMG Pharmaceutical Co (XKRX:058820) Beneish M-Score : -2.41 (As of Jun. 10, 2024)


View and export this data going back to 2001. Start your Free Trial

What is CMG Pharmaceutical Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.41 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for CMG Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

XKRX:058820' s Beneish M-Score Range Over the Past 10 Years
Min: -3.29   Med: -2.35   Max: 3.99
Current: -2.41

During the past 13 years, the highest Beneish M-Score of CMG Pharmaceutical Co was 3.99. The lowest was -3.29. And the median was -2.35.


CMG Pharmaceutical Co Beneish M-Score Historical Data

The historical data trend for CMG Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CMG Pharmaceutical Co Beneish M-Score Chart

CMG Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.35 -2.74 -2.01 -2.39 -2.51

CMG Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.21 -2.31 -2.46 -2.51 -2.41

Competitive Comparison of CMG Pharmaceutical Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, CMG Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CMG Pharmaceutical Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CMG Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where CMG Pharmaceutical Co's Beneish M-Score falls into.



CMG Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of CMG Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.6029+0.528 * 1.0669+0.404 * 2.0374+0.892 * 1.0891+0.115 * 1.097
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9861+4.679 * -0.012112-0.327 * 1.1743
=-2.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ₩23,930 Mil.
Revenue was 22813.683 + 21982.498 + 23537.179 + 25433.043 = ₩93,766 Mil.
Gross Profit was 10396.22 + 9226.32 + 10766.553 + 12911.389 = ₩43,300 Mil.
Total Current Assets was ₩98,317 Mil.
Total Assets was ₩247,380 Mil.
Property, Plant and Equipment(Net PPE) was ₩52,384 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩2,664 Mil.
Selling, General, & Admin. Expense(SGA) was ₩19,163 Mil.
Total Current Liabilities was ₩25,760 Mil.
Long-Term Debt & Capital Lease Obligation was ₩26,406 Mil.
Net Income was 2240.803 + -2647.525 + 2708.026 + 3699.064 = ₩6,000 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ₩0 Mil.
Cash Flow from Operations was 1978.506 + 3735.067 + 1766.484 + 1516.553 = ₩8,997 Mil.
Total Receivables was ₩36,443 Mil.
Revenue was 22953.955 + 21794.327 + 21199.998 + 20143.21 = ₩86,091 Mil.
Gross Profit was 10798.465 + 10686.773 + 10787.288 + 10142.689 = ₩42,415 Mil.
Total Current Assets was ₩148,336 Mil.
Total Assets was ₩234,205 Mil.
Property, Plant and Equipment(Net PPE) was ₩40,945 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩2,295 Mil.
Selling, General, & Admin. Expense(SGA) was ₩17,843 Mil.
Total Current Liabilities was ₩21,416 Mil.
Long-Term Debt & Capital Lease Obligation was ₩20,640 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(23930.233 / 93766.403) / (36442.803 / 86091.49)
=0.255211 / 0.423303
=0.6029

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(42415.215 / 86091.49) / (43300.482 / 93766.403)
=0.492676 / 0.461791
=1.0669

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (98316.759 + 52384.354) / 247379.902) / (1 - (148335.854 + 40944.708) / 234204.682)
=0.390811 / 0.191816
=2.0374

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=93766.403 / 86091.49
=1.0891

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2295.366 / (2295.366 + 40944.708)) / (2663.871 / (2663.871 + 52384.354))
=0.053084 / 0.048392
=1.097

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(19162.576 / 93766.403) / (17842.539 / 86091.49)
=0.204365 / 0.207251
=0.9861

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((26405.518 + 25760.438) / 247379.902) / ((20640.035 + 21415.795) / 234204.682)
=0.210874 / 0.179569
=1.1743

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(6000.368 - 0 - 8996.61) / 247379.902
=-0.012112

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

CMG Pharmaceutical Co has a M-score of -2.41 suggests that the company is unlikely to be a manipulator.


CMG Pharmaceutical Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of CMG Pharmaceutical Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


CMG Pharmaceutical Co (XKRX:058820) Business Description

Traded in Other Exchanges
N/A
Address
Cheongdam-dong 18-20, No. B01, Gangnam-gu, Seoul, KOR, 135-949
CMG Pharmaceutical Co Ltd is the sole pharmaceutical company and an affiliate company of CHA Health Systems. CHA Health Systems are integrated systems which include medical school, pharmacy school, research institutes, general hospitals and many affiliates which are related to stem cell research, biotechnology and pharmaceutical business all over the world.

CMG Pharmaceutical Co (XKRX:058820) Headlines

No Headlines